Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics and a $200 million private placement in February 2026. The company discontinued the development of solnerstotug in October 2025, followed by a workforce reduction. Sensei reported its full-year 2025 financial results and provided a corporate update in March 2026, and reported its third-quarter 2025 financial results in November 2025. The company announced inducement grants in February and March 2026. Over the last 12 months, the stock price has increased significantly.

Traditional demand seasonality is not applicable to Sensei Biotherapeutics, as its revenue generation is not tied to seasonal consumer purchasing patterns. The company's activities revolve around research and development, clinical trials, and strategic partnerships, which are not inherently seasonal.

Sensei Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics using its Tumor Microenvironment Activated Biologics (TMAb™) platform. The TMAb platform creates conditionally active therapeutics that selectively disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. The company's pipeline includes PIKTOR, a multi-node inhibitor of the PI3K/AKT/mTOR pathway, solnerstotug, a conditionally active antibody designed to block the VISTA checkpoint, and SNS-102, SNS-103, and SNS-201, which are active monoclonal antibodies for solid tumors.

Sensei Biotherapeutics is headquartered in Rockville, Maryland, and maintains an office in Boston, Massachusetts.

Sensei Biotherapeutics' brand reputation is shaped by its scientific advancements, clinical trial progress, and strategic corporate decisions. The acquisition of Faeth Therapeutics and the $200 million private placement enhanced its reputation. The decision to discontinue the development of solnerstotug and the subsequent workforce reduction could have negatively impacted its reputation, but the company quickly pivoted with the Faeth Therapeutics acquisition.

Sensei Biotherapeutics has a mix of institutional and individual owners. Institutional investors own approximately 10.50% of the stock. James Peyer is the largest individual shareholder, owning 5.34 million shares.